Propranolol

• UNSPSC Description:

  Propranolol is a nonselective β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively[1]. Propranolol inhibits [3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM[2]. Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy[3].

• Target Antigen:

  Adrenergic Receptor; Bacterial

• Type:

  Natural Products

• Related Pathways:

  Anti-infection;GPCR/G Protein;Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Neurological Disease; Cardiovascular Disease; Endocrinology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/propranolol.html

• Purity:

  99.87

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  OC(COC1=C2C=CC=CC2=CC=C1)CNC(C)C

• Molecular Weight:

  259.34

• References & Citations:

  [1]Galandrin S, et al. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006 Nov;70(5):1575-84. Epub 2006 Aug 1|[2]Briley M, et al. Evidence against beta-adrenoceptor blocking activity of diltiazem, a drug with calcium antagonist properties. Br J Pharmacol. 1980 Aug;69(4):669-73.|[3]Al-Majed AA, et al. Propranolol. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338.|[4]Munabi NC, et al. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation. Stem Cells Transl Med. 2016 Jan;5(1):45-55.Acta Pharm Sin B. 2024 Apr 23.|Am J Pathol. 2023 Apr 21;S0002-9440(23)00132-3.|Bone Res. 2024 Mar 21;12(1):18.|Environ Toxicol. 2023 Dec 2.|Exp Neurol. 2023 Apr 19;114418.|Food Chem Toxicol. 2024 Sep 6:114983.|iScience. 2023 Jul 19.|J Chromatogr B. 2023 Jun 20, 123804.|J Immunother Cancer. 2024 Dec 9;12(12):e009910.|J Pharmaceut Biomed. 2020, 113870.|Nat Commun. 2023 May 2;14(1):2523.|Pharmacol Res Perspect. 2020 Apr;8(2):e00575.|Pharmacol Res Perspect. 2021 Oct;9(5):e00879.|Phytomedicine. 2024 Aug 19:134:155970.|Research Square Print. December 21st, 2022.|Sci Signal. 2020 Nov 24;13(659):eaax0273.|Behav Brain Res. 28 October 2021, 113642.|Biochem Biophys Res Commun. 2023 Mar 21;657:69-79.|bioRxiv. 2024 November 03.|BMC Pulm Med. 2021 Jun 5;21(1):189.|Cell Metab. 2024 Mar 5;36(3):466-483.e7.|Cell. 2024 Nov 26:S0092-8674(24)01311-4.|Chemosphere. 2019 Jun;225:378-387. |Elife. 2024 May 29.|J Endocrinol. 2020 Mar;244(3):459-471.|Psychopharmacology. 2023 Jun 17.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  525-66-6